Chimeric antigen receptor T-cell (CAR-T) therapy has been prosperous in the treatment of patients with various types of relapsed/refractory (R/R) B-cell malignancies including diffuse large B-cell lymphoma (DLBCL), B-cell acute lymphoblastic leukemia (B-ALL), follicular lymphoma (FL), mantle...
Driving gene-engineered T cell immunotherapy of cancer Chimeric antigen receptor (CAR) gene-engineered T cell therapy holds the potential to make a meaningful difference in the lives of patients with terminal c... auraAJohnson,CarHJun - 《Cell Research》 被引量: 77发表: 2017年 Stage grouping...
"The overall goal of our research is to support precision oncology care. Novel therapeutic strategies will help us improve the efficacy of CAR-T cell therapy for patients with non-Hodgkin lymphoma," says David Wald, M.D., Ph.D., of Case Western, Cleveland Medical Center, the study's co-...
Chimeric antigen receptor (CAR) T cells are engineered constructs composed of synthetic receptors that direct T cells to surface antigens for subsequent el... K Newick,E Moon,SM Albelda - 《Molecular Therapy Oncolytics》 被引量: 75发表: 2016年 Adoptive T-Cell Therapy for Solid Tumors Chimeric...
New data on CAR-T therapy, called cilta-cel, suggests the treatment might help halt progression of multiple myeloma for nearly two years.
As of 2022, the FDA has not approved CAR T-cell therapy for treating mesothelioma. This technology does have FDA approval to treat some other forms of cancer. CAR T-cell therapies are an active area of mesothelioma research. Learn More About CAR T-Cell Therapy ...
Accessing Affordability: Overcoming Financial Barriers in CAR T-Cell Therapy Pathways to Affordability: Value-Based Care, Value-Based Insurance Design for Patients With Cancer The Importance of Payment Reform in Cancer Care Behind the Scenes of CAR T-Cell Therapy: The Role of the Pharmacist Student...
4. Adoptive Cell Therapy Adoptive cell therapy is a treatment where doctors collect a patient’s immune cells (usually T cells) and modify them outside the body to make them better at fighting mesothelioma. The most well-known example is CAR T cell therapy. CAR T cell therapy involves: Dra...
Secretion of bispecific protein of anti-PD-1 fused with TGF-beta trap enhances antitumor efficacy of CAR-T cell therapy Mol Ther Oncolytics, 21 (2021), pp. 144-157 View PDFView articleGoogle Scholar 34 M. Kwon, C.G. Kim, H. Lee, et al. PD-1 blockade reinvigorates bone marrow CD8(...
in T cell-based im- munotherapies, more importantly, next-generation chimeric antigen receptor (CAR)-T cells [4]. CAR-T cell therapy includes the genetic modification of patients’ autologous T cells or allograft cells to effi- ciently express a CAR involving a fusion protein of a se- lec...